Emerging drugs for chemotherapy-induced emesis

Bibliography

• DE BOER-DENNERT M, DE WIT R, SCHMITZ PI et al.: Patient perceptions of the side effects of chemotherapy: the influence of the 5-HT3 antagonists. Br. J. Cancer (1997) 76:1055-1061.
   PubMed Web of Science ®Google Scholar
• LACHAINE J, YELLE L, KAIZER L, DUFOURA, HOPKINS S, DEUSON R: Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Supp. Cancer Therapy (2005) 2:181-187.
   PubMedGoogle Scholar
• OSOBA D, ZEE B, WARR D, LATREILLE J, KAIZER L, PATER J: Effect of post-chemotherapy nausea and vomiting on health related quality of life. Support Care Cancer (1997) 5:307-313.
   PubMed Web of Science ®Google Scholar
• KRIS MG: Why do we need another antiemetic? J. Clin. Oncol. (2003) 21:4077-4080.
   PubMed Web of Science ®Google Scholar
• HICKOK JT, ROSCOE JA, MORROW GR, KING DK, ATKINS JN, FITCH JR: Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. Cancer (2003) 97:2880-2886.
   PubMed Web of Science ®Google Scholar
• GRUNBERG SM, DEUSON R, MAVROS P et al.: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: perception versus reality. Cancer (2004) 100:2261-2268.
   PubMed Web of Science ®Google Scholar
• BERGER AM, CLARK-SNOW RA: Adverse effects of treatment. In: Principles and Practice of Oncology. VT DeVita Jr, S Helman, S Rosenberg (Eds), Lippincott Williams & Wilkins, Philadelphia, US (2001):2869-2880.
   Google Scholar
• GRALLA RJ, OSOBA D, KRIS MG et al.: Recommendations for the use of antiemetics: evidence-based clinical practice guidelines. J. Clin. Oncol. (1999) 17:2971-2994.
   PubMed Web of Science ®Google Scholar
• HESKETH PJ, KRIS MG, GRUNBERG SM et al.: Proposal for classifying the acute emetogenicity of cancer chemotherapy. J. Clin. Oncol. (1997) 15:103-109.
   PubMed Web of Science ®Google Scholar
• OSOBA D, ZEE B, PATER J, WARR D, LATREILLE J, KAIZER L: Determinants of postchemotherapy nausea and vomiting in patients with cancer. J. Clin. Oncol. (1997) 15:116-123.
   PubMed Web of Science ®Google Scholar
• PEREZ EA: 5-HT3 antiemetic therapy for patients with breast cancer. Breast Cancer Res. Treat. (1999) 57:207-214.
   PubMed Web of Science ®Google Scholar
• DEWITT R, HERRSTEDT J, RAPOPORT B et al.: The oral NK-1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled Phase III clinical trials. Eur. J. Cancer (2004) 40:403-410.
   PubMed Web of Science ®Google Scholar
• HESKETH PJ: New treatment options for chemotherapy-induced nausea and vomiting. Support Care Cancer (2004) 12:550-554.
   PubMed Web of Science ®Google Scholar
• MANTOVANI G, MACCIO A, ASLEXANDRO B et al.: Comparison of granisetron versus ondansetron versus tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer (1996) 77:941-948.
   PubMed Web of Science ®Google Scholar
• NAVARI RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents. J. Support. Oncol. (2003) 1:89-103.
   PubMedGoogle Scholar
• KOELLER JM, AAPRO MS, GRALLA RJ et al.: Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer (2002) 10:517-518.
   PubMed Web of Science ®Google Scholar
• KRIS MG, PENDERGRAS KB, NAVARI RM et al.: Prevention of acute emesis following high dose cisplatin with the combination of oral ondnasetron and dexamethasone. J. Clin. Oncol. (1997) 15:2135-2138.
   PubMed Web of Science ®Google Scholar
• HESKETH PJ, HARVEY WH, HARKER WG et al.: A randomized double blind comparison of intravenous ondansetron in combination with intravenous dexamethasone in the prevention of high dose cisplatin-induced emesis. J. Clin. Oncol. (1994) 12:596-600.
   PubMed Web of Science ®Google Scholar
• PEREZ EA, NAVARI RM, KAPLAN HG et al.: Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer (1997) 5:31-37.
   PubMed Web of Science ®Google Scholar
• THE ITALIAN GROUP FOR ANTI-EMETIC RESEARCH: Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N. Engl. J. Med. (1995) 332:1-5.
   PubMed Web of Science ®Google Scholar
• THE ITALIAN GROUP FOR ANTI-EMETIC RESEARCH: Double blind dose finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. N. Engl. J. Med. (1998) 16:2937-2942.
   Google Scholar
• BECK TM, YORK M, CHANG A et al.: Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Cancer Invest. (1997) 15:297-303.
   PubMed Web of Science ®Google Scholar
• KAIZER L, WARR D, HOSKINS O et al.: Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a Phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. (1994) 12:1050-1057.
   PubMed Web of Science ®Google Scholar
• THE ITALIAN GROUP FOR ANTIEMETIC RESEARCH: Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J. Clin. Oncol. (2004) 22:725-729.
   PubMed Web of Science ®Google Scholar
• SIMPSON K, SPENCER CM, MCCLELLAN KJ: Topisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs (2000) 59:1297-1315.
   PubMed Web of Science ®Google Scholar
• KIMURA E, NIIMI E, WATANABE A et al.: Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho (1996) 23:477-481.
   PubMedGoogle Scholar
• TAGUCHI T, TSUKAMOTO F, WATANABE T et al.: Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho (1999) 26:1163-1170.
   PubMedGoogle Scholar
• HESKETH PJ: Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. (2000) 18:163-173.
   PubMed Web of Science ®Google Scholar
• HESKETH PJ, NAVARI RM, GROTE T et al.: Double blind randomized comparison of the antiemetic efficacy of intravenous dolasetron and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J. Clin. Oncol. (1996) 14:2242-2249.
   PubMed Web of Science ®Google Scholar
• NAVARI RM, GANDARA D, HESKETH P et al.: Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J. Clin. Oncol. (1995) 13:1242-1248.
   PubMed Web of Science ®Google Scholar
• NAVARI RM, KOELLER JM: Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists. Ann. Pharmacother. (2003) 37:1276-1286.
   PubMed Web of Science ®Google Scholar
• ROILA F, WARR D, CLARK-SNOW R et al.: Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer (2005) 13(2):104-108.
   PubMed Web of Science ®Google Scholar
• LATREILLE J, PATER J, JOHNSTON D et al.: Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J. Clin. Oncol. (1998) 16:1174-1178.
   PubMed Web of Science ®Google Scholar
• NAVARI RM, MADAJCWICZ S, ANDERSON N et al.: Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J. Clin. Oncol. (1995) 13:2408-2416.
   PubMed Web of Science ®Google Scholar
• THE ITALIAN GROUP FOR ANTIEMETIC RESEARCH: Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N. Engl. J. Med. (2000) 342:1554-1559.
   PubMed Web of Science ®Google Scholar
• GELING O, EICHLER H: Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J. Clin. Oncol. (2005) 23:1289-1294.
   PubMed Web of Science ®Google Scholar
• HICKOK JT, ROSCOE JA, MORROW GR et al.: 5-HT3 receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncol. (2005) 6:765-772.
   PubMed Web of Science ®Google Scholar
• EISENBERG P, MACKINTOSH FR, RITCH P et al.: Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann. Oncol. (2004) 15:330-337.
   PubMed Web of Science ®Google Scholar
• EISENBERG P, FIGUEROA-VADILLO J, ZAMORA R et al.: Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Results of a Phase III, single-dose trial versus dolasetron. Cancer (2003) 98:2473-2482.
   PubMed Web of Science ®Google Scholar
• GRALLA R, LICHINITSER M, VAN DER VEGT S et al.: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol. (2003) 14:1570-1577.
   PubMed Web of Science ®Google Scholar
• AAPRO MS, BERTOLI L, LORDICK F: Palonosetron is effective in preventing acute and delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer (2003) 11:391 (abstract A-17).
   Google Scholar
• CARTMELL AD, FERGUSON S, YANAGIHARA R et al.: Protection against chemotherapy-induced nausea and vomiting is maintained over multiple cycles of moderately or highly emetogenic chemotherapy by palonosetron, a potent 5-HT3 receptor antagonist. Proc. Am. Soc. Clin. Oncol. USA (2003) 756:3041 (Abstract).
   Google Scholar
• KRIS MG, RADFORD JE, PIZZO BA, INABINET R, HESKETH A, HESKETH PJ: Use of a NK-1 receptor antagonist to prevent delayed emesis after cisplatin (letter). J. Natl. Cancer Inst. (1997) 89:817-818.
   PubMed Web of Science ®Google Scholar
• HESKETH PJ, GRALLA RJ, WEBB RT et al.: Randomized Phase II study of the neurokinin-1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J. Clin. Oncol. (1999) 17:338-343.
   PubMed Web of Science ®Google Scholar
• NAVARI RM, REINHARDT RR, GRALLA RJ et al.: Reduction of cisplatin-induced emesis by a selective neurokin-1 receptor antagonist. N. Engl. J. Med. (1999) 340:190-195.
   PubMed Web of Science ®Google Scholar
• COCQUYT V, VAN BELLE S, REINHARDT RR et al.: Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur. J. Cancer (2001) 37:835-842.
   PubMed Web of Science ®Google Scholar
• CAMPOS D, PEREIRA JR, REINHARDT RR et al.: Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J. Clin. Oncol. (2001) 19:1759-1767.
   PubMed Web of Science ®Google Scholar
• VAN BELLE S, LIECHINITSER M, NAVARI RM et al.: Prevention of cisplatin- induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer (2002) 94:3032-3041.
   PubMed Web of Science ®Google Scholar
• CHAWLA SP, GRUNBERG SM, GRALLA RJ et al.: Establishing the dose of the oral NK-1 antagonist aprepitant for chemotherapy-induced nausea and vomiting. Cancer (2003) 97:2290-2300.
   PubMed Web of Science ®Google Scholar
• HESKETH PJ, GRUNBERG SM, GRALLA RJ et al.: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind placebo-controlled trial in patients receiving high-dose cisplatin – the aprepitant protocol 052 study group. J. Clin. Oncol. (2003) 21:4112-4119.
   PubMed Web of Science ®Google Scholar
• POLI-BIGELLI S, ROGRIGUES-PEREIRA J, CARIDES AD et al.: Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer (2003) 97:3090-3098.
   PubMed Web of Science ®Google Scholar
• DEWITT R, HERRSTEDT J, RAPOPORT BL et al.: Addition of the oral NK-1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J. Clin. Oncol. (2003) 21:4105-4111.
   PubMed Web of Science ®Google Scholar
• NAVARI RM: Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev. Anti-Cancer Ther. (2004) 4(5):715-724.
   PubMed Web of Science ®Google Scholar
• DANDO TM, PERRY CM: Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs (2004) 64:777-794.
   PubMed Web of Science ®Google Scholar
• AAPRO MS, SCHMOLL HJ, POLI-BIGELLI S et al.: Comparison of aprepitant combination regimen with 4-day ondansetron + 4-day dexamethasone for prevention of acute and delayed nausea/vomiting after cisplatin chemotherapy. Proceedings of the 41st Annual Meeting. Orlando, USA (2005):730s (Abstract 8007).
   Google Scholar
• WARR DG, HESKETH PJ, GRALLA RJ et al.: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J. Clin. Oncol. (2005) 23:2822-2830.
   PubMed Web of Science ®Google Scholar
• BYMASTER FP, CALLIGARO D, FALCONE J et al.: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology (1996) 14:87-96.
   PubMed Web of Science ®Google Scholar
• BYMASTER FP, FALCONE JF, BAUZON D et al.: Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine. Eur. J. Pharmacol. (2001) 430:341-349.
   PubMed Web of Science ®Google Scholar
• ALLISON DB, CASEY DE: Antipsychotic-associated weight gain: a review of the literature. J. Clin. Psychiatry (2001) 62:22-31.
   PubMed Web of Science ®Google Scholar
• HALE AS: Olanzapine. Br. J. Hosp. Med. (1997) 58:443-445.
   Google Scholar
• GOLDSTEIN LE, SPORN J, BROWN S et al.: New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics (1999) 40:438-443.
   PubMed Web of Science ®Google Scholar
• JACKSON WC, TAVERNIER L: Olanzapine for intractable nausea in palliative care patients. J. Palliative Med. (2003) 6:251-255.
   PubMedGoogle Scholar
• PASSIK SD, KIRSH KL, THEOBALD DE et al.: A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J. Pain Symptom Manag. (2003) 25:485-489.
   PubMed Web of Science ®Google Scholar
• PASSIK SD, LUNDBERG J, KIRSH K et al.: A pilot exploration of the antiemetic activity of olanzapine (Zyprexa) for the relief of nausea in patients with advanced cancer and pain. J. Pain Symptom Manag. (2002) 23:526-532.
   PubMed Web of Science ®Google Scholar
• PIRL WF, ROTH AJ: Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology (2000) 9:84-87.
   PubMed Web of Science ®Google Scholar
• SRIVASTAVA M, BRITO-DELLAN N, DAVIS MP, LEACH M, LAGMAN R: Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J. Pain Symptom Manag. (2003) 25:578-582.
   PubMed Web of Science ®Google Scholar
• PASSIK S, NAVARI RM, JUNG S: A Phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients receiving chemotherapy. Cancer Invest. (2004) 22:383-388.
   PubMed Web of Science ®Google Scholar
• CLEELAND CS, MENDOZA TR, WANG XS et al.: Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer (2000) 89(7):1634-1646.
   PubMed Web of Science ®Google Scholar
• NAVARI RM, EINHORN LH, LOEHRER PJ et al.: A Phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer (2005) 13:529-534.
   PubMed Web of Science ®Google Scholar
• GUTTUSO T, ROSCOE J, GRIGGS J: Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet (2003) 361:1703-1705.
   PubMed Web of Science ®Google Scholar
• BORISON HL, MCCARTHY LE: Neuropharmacology of chemotherapy-induced emesis. Drugs (1983) 25:8-17.
   PubMed Web of Science ®Google Scholar
• YATES BJ, GRELOT L, KERMAN IA, BALABAN CD, JAKUS J, MILLER AD: Organization of the vestibular inputs to nucleus tractus solitarius and adjacent structures in cat brain stem. Am. J. Physiol. (1994) 267(4 Pt 2):R974-R983.
   PubMed Web of Science ®Google Scholar
• NAVARI RM, KAPLAN HG, GRALLA RJ, GRUNBERG SM, PALMER R, FITTS D: Efficacy and safety of granisetron, a selective, 5-hydroxytryptamine receptor antagonist, for the prevention of nausea and vomiting induced by high dose cisplatin. J. Clin. Oncol. (1994) 12:2204-2210.
   PubMed Web of Science ®Google Scholar
• PEREZ EA: Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J. Clin. Oncol. (1995) 13:1036-1043.
   PubMed Web of Science ®Google Scholar
• SANGER GJ: The involvement of the 5-HT3 receptors in visceral function. In: Central and Peripheral 5-HT3 Receptors. M Harmon (Ed.), Academic Press, London, UK (1992):207-255.
   Google Scholar
• TAVORATH FD, HESKETH PJ: Drug treatment of chemotherapy-induced delayed emesis. Drugs (1996) 52:639-648.
   PubMed Web of Science ®Google Scholar
• RUDD JA, NAYLOR RJ: Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret. Neuropharmacology (1994) 33:1607-1608.
   PubMed Web of Science ®Google Scholar
• ANDREWS PLR: 5-HT3 receptor antagonists and antiemesis. In: 5-Hydroxytryptamine-3 Receptor Antagonists. FD King, BJ Jones, GJ Sanger (Eds), CRC Press, Boca Raton/London, US/UK (1994).
   Google Scholar
• DIEMUNSCH P, GRELOT L: Potential of substance P antagonists as antiemetics. Drugs (2000) 60:533-546.
   PubMed Web of Science ®Google Scholar
• FASTH KJ, BERGSTROM M, KILPATRICK G: Brain uptake and receptor binding of two C11 labeled selective high affinity NK-1 antagonists, GR203040 and GR 205171. J. Labeled Comp. Radiopharm. (1997) 40:665-667.
   Google Scholar
• TATTERSALL FD, RYCROFT W, FRANCIS B et al.: Tachykinins NK-1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology (1996) 35:1121-1129.
   PubMed Web of Science ®Google Scholar
• MINAMI M, ENDO T, KIKUCHI K et al.: Antiemetic effects of sendide, a peptide tachykinin NK-1 receptor antagonist, in the ferret. Eur. J. Pharmacol. (1998) 363:49-55.
   PubMed Web of Science ®Google Scholar
• MINAMI M, ENDO T, YOKODA H et al.: Effects of CP-99,994, a tachykinin NK-1 receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK-1 and 5-HT3 receptors. Eur. J. Pharmacol. (2001) 428:215-220.
   PubMed Web of Science ®Google Scholar
• TATTERSALL FD, RYCROFT W, CUMBERBATCH M et al.: The novel NK-1 receptor antagonist MK-869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology (2000) 39:652-663.
   PubMed Web of Science ®Google Scholar
• MCCREA JB, MAJURNDAR AK, GOLDBERG MR et al.: Effects of the neurokinin-1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin. Pharmacol. Ther. (2003) 74:17-24.
   PubMed Web of Science ®Google Scholar
• MAJURNDAR AK, MCCREA JB, PANEBIANCO DL et al.: Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin. Pharmacol. Ther. (2003) 74:150-156.
   PubMed Web of Science ®Google Scholar
• NYGREN P, HANDE K, PETTY KJ et al.: Lack of effect of aprepitant on the pharmokinetics of docataxel in cancer patients. Cancer Chemother. Pharmacol. (2005) 55:609-616.
   PubMed Web of Science ®Google Scholar
• HESSELINK MB, TUINSTRA T, DIJKSMAN J et al.: Pharmacological characteristics of SLV 323, a novel CNS-active NK-1 Antagonist. Society of Neuroscience. New Orleans, USA (2003):33 (Abstract).
   Google Scholar
• REILLY RT: BNP-7787. Drugs (2004) 7(1):64-69.
   PubMed Web of Science ®Google Scholar
• KRIS MG, HESKETH PJ, HERRSTEDT J et al.: Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer (2005) 13(2):85-96.
   PubMed Web of Science ®Google Scholar
• FABI A, BARDUAGNI M, LAURO S et al.: Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer (2003) 11:156-161.
   PubMed Web of Science ®Google Scholar